Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Charles Dharmani
TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment
ABSTRACT Aims To assess hepatic safety data of pexidartinib in adult patients with tenosynovial giant cell tumor (TGCT) from the retrospective 5-year evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program. Patients & methods We analyzed data collected from healthcare professionals, patients, pharmacies, and distributors who participated in the tREMS Program from August 2019 to June 2024.
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Tenosynovial giant cell tumors (TGCT), formerly referred to as pigmented villonodular synovitis (PVNS), are rare, benign [1] and locally aggressive neoplasms affecting the synovial membrane lining joints, bursae and tendon sheaths [2,3]. Disease presentation is heterogeneous and ranges from mildly asymptomatic to debilitating symptoms, including severe pain, stiffness, swelling and limited range of motion [4].
Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma | Future Oncology
Peripheral T-cell lymphomas (PTCL) are a rare and aggressive form of non-Hodgkin's lymphoma (NHL) that affect mature T- and natural killer cells. In the USA, the incidence of NHL is estimated to be around 80,000 cases per year and PTCL only accounts for up to 10% of all NHL cases [1–3]. PTCL is a heterogeneous disease that can be characterized into more than 25 specific subtypes based on clinically distinct features [4].
Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes | Future Oncology
Future OncologyAhead of Print Research ArticleOpen Access Published Online: Abstract Aim: Elderly acute myeloid leukemia (AML) patients are often not treated with antileukemic therapy due to their poor overall health condition, leaving supportive care as the sole treatment option. Objective: To evaluate patient characteristics, treatment patterns and outcomes of elderly patients with AML who are treated with supportive care only.
Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database | Future Oncology
Future OncologyAhead of Print Research ArticleOpen Access Abstract Background: Without treatment, acute myeloid leukemia (AML) is rapidly fatal. Nevertheless, a large proportion of elderly AML patients do not receive any treatment. Aim: To characterize the demographics, comorbidities, survival and prognostic factors of elderly AML patients who do not receive any AML treatment or supportive care (SC).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Charles
Contact Charles, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack